Christopher Wright

Dr. Christopher Wright

University of Pennsylvania
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
CWChristopher Wright
Christopher Wright
MLMichael J. LaRiviere
Michael J. LaRiviere
JBJonathan A. Baron
Jonathan A. Baron
CUChibueze Uche
Chibueze Uche
YXYing Xiao
Ying Xiao
JPJohn P. Plastaras
John P. Plastaras

3 August 2016 in Cell Cycle
Verified
Journal Article
Closed access
BSBrittany A. Simone
Brittany A. Simone
TDTu Dan
Tu Dan
APAjay Palagani
Ajay Palagani
LJLianjin Jin
Lianjin Jin
SHSunny Y. Han
Sunny Y. Han
NSNicole L. Simone
Nicole L. Simone
Purpose: Metastatic breast cancer is devastating and triple negative breast cancers (TNBC) have a higher propensity for metastasis. Improved local control upfront in this aggressive cancer could potentially decrease its propensity toward metastasis. We sought to determine if using caloric restriction (CR) as a systemic therapy, combined with radiation therapy (IR) to the primary tumor, may impact metastatic disease. Methods: An orthotopic mouse model using a highly metastatic, luciferase-tagged TNBC cell line (4T1), was used to generate palpable tumors. Mice were then treated with CR, IR, and a combination of the two. In vivo imaging was performed for metastatic evaluation. Molecular evaluation of the tumors was performed, generating a mechanistic hypothesis for CR, which was then tested with pertinent pathway inhibition in the model. Results: CR significantly increased the time to developing metastases, decreased the overall number and volume of lung metastases, and increased survival. CR decreased proliferation, increased apoptosis and globally downregulated the IGF-1R signaling pathway. Adding an IGF-1R/INSR inhibitor to local IR in vivo accomplished a decrease in metastases similar to CR plus IR, demonstrating the importance of the IGF-1R signaling pathway, and underscoring it as a possible mechanism for CR. Conclusions: CR decreased metastatic burden and therefore may complement cytotoxic therapies being used in the clinical setting for metastatic disease. Downregulation of the IGF-1R pathway, is in part responsible for this response and modulating IGF-1R directly resulted in similar improved progression-free survival. The novel use of CR has the potential to enhance clinical outcomes for patients with metastatic breast cancer.

25 June 2020 in Blood
Verified
Journal Article
Closed access
PDF file
MBMichael S. Binkley
Michael S. Binkley
MRM. Shahzad Rauf
M. Shahzad Rauf
SMSarah A. Milgrom
Sarah A. Milgrom
CPChelsea C. Pinnix
Chelsea C. Pinnix
RTRichard W Tsang
Richard W Tsang
RHRichard T. Hoppe
Richard T. Hoppe
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon histologic variant, and the optimal treatment for stage I-II NLPHL is undefined. We conducted a multi­center retrospective study including patients ≥16 years with stage I-II NLPHL diagnosed from 1995­2018 receiving all forms of management including radiotherapy (RT), combined modality therapy (CMT=RT+chemotherapy), chemotherapy (CT), observation after excision, rituximab and RT, and single agent rituximab (R). End points were progression­free survival (PFS), freedom from transformation, and overall survival (OS) without statistical comparison between management groups. We identified 559 patients with median age 39 years, 72.3% being male, and 54.9% having stage I disease. Median follow up was 5.5 years (IQR=3.1-10.1). 5-year PFS and OS for the entire cohort were 87.1% (95%CI=83.6-90.0%) and 98.3% (95%CI=96.4-99.2%), respectively. Primary management was RT alone (n=257, 46.0%), CMT (n=184, 32.9%), CT alone (n=47, 8.4%), observation (n=37, 6.6%), rituximab and RT (n=19, 3.4%), and rituximab alone (n=15, 2.7%). 5-year PFS rates were 91.1% (95%CI=85.3-94.7%) after RT, 90.5% (95%CI=84.8-94.1%) after CMT, 77.8% (95%CI=61.3-88.0%) after chemotherapy, 73.5% (95%CI=50.6-87.0%) after observation, 80.8% (95%CI=41.0-95.1%) after rituximab and RT, and 38.5% (95%CI=14.0-62.8%) after rituximab alone. For the RT cohort but not the CMT cohort, variant immunoarchitectural pattern and number of sites>2 were associated with worse PFS (P2 (P=0.0006). OS for patients with stage I-II NLPHLwas excellent following all managements.

1 July 2016 in Current Opinion in Clinical Nutrition and Metabolic Care
Verified
Journal Article
Closed access
CWChristopher Wright
Christopher Wright
NSNicole L. Simone
Nicole L. Simone
This article reviews the impact the obese state has on malignancy through inflammation and immune dysregulation using recent excerpts from the medical literature. The obese state creates a proinflammatory endocrinologic milieu altering cellular signaling between adipocytes, immunologic cells, and epithelial cells, leading to the over-activation of adipose tissue macrophages and the upregulation of compounds associated with carcinogenesis. Obesity correlates with a deficiency in numerous immunologic cells, including dendritic cells, natural killer cells, and T cells. In part, this can be attributed to a recent finding of leptin receptor expression on these immune cells and the upregulation of leptin signaling in the obese state. A number of clinical trials have demonstrated the feasibility of a high-fat, low-carbohydrate diet as an adjuvant treatment for cancer, and current trials are investigating the impact of this intervention on disease outcomes. In preclinical trials, a ketogenic diet has been shown to impede tumor growth in a variety of cancers through anti-angiogenic, anti-inflammatory, and proapoptotic mechanisms. Obesity is becoming more prevalent and its link to cancer is clearly established providing a rationale for the implementation of dietary interventions as an adjuvant therapeutic strategy for malignancy.


1 October 2021 in Oral Oncology
Verified
Journal Article
Closed access
CWChristopher Wright
Christopher Wright
DLDaniel Y. Lee
Daniel Y. Lee
DSDavid Shimunov
David Shimunov
RCRuben Carmona
Ruben Carmona
ABAndrew R. Barsky
Andrew R. Barsky
SSSamuel Swisher-McClure
Samuel Swisher-McClure